miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells-Reference-Cited by-同舟云学术

miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells

Published:2013-04-17 Issue:1-2 Volume:379 Page:69-75
ISSN:0300-8177
Container-title:Molecular and Cellular Biochemistry
language:en
Short-container-title:Mol Cell Biochem

Author:

Zhu Chen,Li Jie,Cheng Gong,Zhou Hai,Tao Liangjun,Cai Hongzhou,Li Pu,Cao Qiang,Ju Xiaobing,Meng Xiaoxin,Wang Meilin,Zhang Zhengdong,Qin Chao,Hua Lixin,Yin Changjun,Shao Pengfei

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11010-013-1628-4.pdf

Reference25 articles.

1. Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28:15–33

2. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, Kelly K (2012) MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 32(3):296–306

3. Ozcan S (2009) MiR-30 family and EMT in human fetal pancreatic islets. Islets 1:283–285

4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulation of TCONS_00006091 contributes to the elevated risk of oral squamous cell carcinoma by upregulating SNAI1, IRS and HMGA2;Scientific Reports;2024-04-26

2. HMGA2 promotes cancer metastasis by regulating epithelial–mesenchymal transition;Frontiers in Oncology;2024-02-01

3. Epigenetic regulation of androgen dependent and independent prostate cancer;Advances in Cancer Research;2024

4. SNHG11: A New Budding Star in Tumors and Inflammatory Diseases;Mini-Reviews in Medicinal Chemistry;2023-11

5. MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer;Pathology - Research and Practice;2023-08